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Product and process design: towards industrial TE manufacturing 
Ioannis Papantoniou, Athanasios Mantalaris, Maarten Sonnaert, Toon Lambrechts, Jean-
Marie Aerts, Liesbet Geris, Jan Schrooten. 
 
Learning Objectives 
 An understanding of the challenges that tissue engineered products will face at the 
translational phase 
 Overview of the sequence of process steps involved in tissue engineering 
manufacturing 
 Possible strategies to manufacture tissue engineered products 
 How current technologies fit and can be best used for autologous and allogeneic 
tissue engineered products 
 How to determine quality characteristics and link them to the production process 
environment 
 Using monitoring and control for real time follow up of TE product maturation 
 Understand the importance of models for the design of novel tissue engineered 
products and bioprocess optimization. 
 What is downstream process in the case of TE manufacturing 
 Integration of process steps in larger schemes, ‘whole bioprocessing’ approach 
 
Abstract 
As the field of Tissue Engineering matures and the transition from bench-scale to large-scale 
industrialized production is realized, a new set of biological and technological challenges 
arises.  To bring tissue engineered products to the clinic and subsequently to the market will 
require the application of engineering principles and practices to achieve control, 
reproducibility, automation, validation and safety of the process and the product. The 
successful translation will require contributions from fundamental research (from 
developmental biology to advanced modeling mathematical approaches) but also existing 
industrial practice (biopharma), especially on automation, quality assurance and regulation.   
Keywords 
Autologous and allogeneic, current good manufacturing practice (cGMP), Bioprocess 
development and optimization, Quality control, Product design, Downstream processing 
Snapshot Summary 
 The translation of tissue engineered products to the market will require a new set of 
technological challenges to be addressed. In order to achieve this there is a need for 
engineering principles to be applied to bring biologic discoveries to the market. 
 There are two main categories of Tissue Engineered products based on the origin of 
the cells in the TE (i) allogeneic therapies may result in ‘off-the-shelf’ products ready 
to be administered to patients, (ii) autologous ‘patient-specific’ therapies based on 
the use of the patient’s own cells for the production of the TE product.   
 To produce TE products without risk of contamination, GMP grade raw materials and 
facilities should be the base for TE manufacturing. 
 The production of TE products will consist on a series of process steps which need to 
be designed, understood and optimized. Currently there is lack of process 
characterization while manual operations are still dominant. 
 Quality control for TE products should take into account the complexity of the 
product. A mutliscale approach characterizing cells but also tissue properties (3D) will 
be needed hence apart from standard techniques for cell characterization novel ones 
should be developed. 
 For TE products the end product is linked directly to the process due to the 
responsiveness of the cultured cells to their environment. Monitoring and controlling 
the culture environment may be indirectly linked to the quality properties of the TE 
construct.  
 Data derived from sensors should be analysed by algorithms, if possible, online to 
extract maximum information and aid in decision making during manufactruring 
 Bioreactor systems can delivery sufficient volumes for industrial production of 
allogeneic TE products while providing control options and automation potential 
which is crucial for  autologous treatments 
 Downstream processes will be required for the harvest and recovery of cells, their 
purification and potentially re-seeding to scaffolds. Currently there is lack of 
information on this aspect of TE manufacturing however in a commercial setting this 
will become necessary 
 Mathematical modeling may be applied for the design of TE constructs by running 
cost effectively in silico experiments. This can be applied both for in vitro as well as in 
vivo case studies. Models characterizing cell-scaffold interactions, cell signaling , 
tissue growth and in vivo behavior should eventually be linked across scales. 
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The steady increase of early- and late-stage clinical trials involving cell therapy applications, 
as well as the presence of approved commercial tissue engineered (TE) products in the 
market, strongly indicates that the cell therapy industry is on its way to evolve into a novel 
healthcare sector (Mason et al., 2013, Mason and Manzotti, 2010). Apart from clinical 
efficacy, TE products will need to be manufactured in cost-effective, scalable and robust 
bioprocesses that  at the same time also meet the requirements of regulatory bodies in 
terms of quality control (QC) and good manufacturing practice (GMP) (dos Santos et al., 
2011, Ratcliffe et al., 2011). TE product manufacturing will require a series of process steps 
from biopsy harvest and stem cell isolation for autologous strategies, or starting from master 
cell bank frozen vials for allogeneic strategies, to end product formulation and implantation. 
Currently, stem and progenitor cell isolation, expansion, differentiation and 3D tissue 
construct formation consist of a series of conventional manual and static techniques (Figure 
1), heavily depending on operator expertise. Hence these process steps are still suboptimal 
and uncontrolled, with high risk of contamination and processing inconsistency (Mason and 
Hoare, 2007, Placzek et al., 2009). 
 
 Figure 1: Sequence of units of operations involved in TE manufacturing. Processes from biopsy acquisition (or master cell bank (MCB)) through cell expansion, cell harvest condensation and formulation are all components of the pipeline that will be required for cell and tissue engineered construct production.  
In addition, manual operations are an additional source of complexity to TE construct 
production, where the fusion of numerous biological ‘raw’ materials is required to 
manufacture complex final products. Furthermore end product quality attribute profile (such 
as cell number, phenotype, extracellular matrix content/morphology) will be constantly 
affected by the bioprocess environment. Hence the translation of laboratory-scale produced 
three dimensional (3D) engineered constructs to clinically effective and economically viable 
products requires the development of efficient and robust manufacturing processes that will 
ensure consistent product quality according to regulatory requirements addressing key 
barriers to translation (French et al., 2014). An increasing number of recent review papers is 
highlighting the need for a concerted effort, between academic, clinical, regulatory and 
industrial partners in order to outline the landscape for research and translation suggesting a 
global standardization and harmonization (ESF how to advance cell-based Advanced 
Therapies in Europe: 
http://www.esf.org/index.php?eID=tx_nawsecuredl&u=0&file=fileadmin/be_user/research_
areas/emrc/RNPs/Remedic/2013/White_paper_REMEDIC_22_July_2013_final_v1.pdf&t=13
96269348&hash=e5e0dbdbaa744fed8a1123d88adbe12571469553). This global attempt 
should follow rational and orchestrated approaches rather than trial and error ones, from 
stem cell niche to process-scale (Kirouac and Zandstra, 2008), taking into account the 
development of commercially viable and robust bioprocesses that will ultimately allow for a 
cost effective production of TE products 
(http://scec.gatech.edu/sites/default/files/StemCellEngineering-CompleteReport.pdf), 
(Nerem, 2012). 
23.1.2 Satisfying cGMP requirements 
cGMP regulations were first introduced by the US Food and Drug Administration and are also 
implemented in Europe (Commission Directive 2003/94/EC). cGMP regulations aim to 
ensure the identity, quality, safety, purity and potency of TE products. (FDA cGMP 
guidelines,http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidance
s/ucm064971.htm). All clinical trials currently in the U.S. are obliged to produce all cell 
products following FDA cGMP guidelines (Code 21 CFR 210–211, 312, 600, and 1271). 
Equivalent regulatory rules have also been established in Europe (EU Directive 2003/94/EC) 
and many other countries and regions internationally (ICHQ7). To achieve this, all processing 
stages should adhere to the guidelines by using cGMP-grade reagents and materials as well 
as cGMP-compliant systems that operate under current cGMP conditions. Besides the 
manufacturing process itself, also a quality management system that can precisely monitor, 
measure, and record critical quality parameters in each processing step is required. This 
quality management systems need to ensure that the final TE product is manufactured 
according to the desired safety, quality, quantity, purity, and potency requirements of the 
targeted clinical application.  Hence to obtain effective and clinically relevant cell-based 
therapeutic products manufacturing in stringent and reliable context is needed. More 
specifically for TE product manufacturing all ‘raw’ materials, like biomaterials, substrates, 
culture media or biomolecules (growth factors) that create an adequate environment for the 
propagation of stem cells in an undifferentiated state and/or their controlled differentiation 
into more mature cells, should (at the start of the process) individually all satisfy cGMP 
requirements. 
cGMP requirements were established to be flexible in order to allow each manufacturer to 
decide individually how to best implement the necessary controls by using scientifically 
sound design, processing methods, and testing procedures. The "c" in cGMP stands for 
"current," meaning that technologies and systems that are up-to-date should be employed 
in order to comply with the existing regulations. However given the complexity and range of 
the expected TE products a variety of customized ‘rules’ would be required at least at the 
early phases to conduct a product-based characterization  and therefore it should be noted 
that cGMPs are only minimum requirements. Approved cell-based advanced therapeutic 
medicinal products (ATMPs) such as MACI (matrix-induced autologous chondrocyte 
implantation), aiming to repair cartilage defects (Genzyme/Sanofi, France) and 
ChondroCelect® (TiGenix, Belgium) are the only licensed cell-based ATMPs on the market in 
Europe and could provide influential blueprints for their cGMP procedures (Warren, 2013). 
TE Tissue Engineering 
ATMP Advanced therapeutic medicinal product 
EMA European medicines agency 
FDA Food and Drug administration 
cGMP Current good manufacturing practice 
QbD Quality by Design 
DoE Design of experiments 
CQA Critical quality attribute 
CPP Critical process parameter 
Table 1: Abbreviations for commonly used terms related to Tissue Engineering 
manufacturing 
23.1.3 Quality by design: pathway for optimized translational strategies  
Quality by design (QbD) is a systematic approach to drive development that begins with 
predefined objectives and emphasizes product and process understanding and process 
control, based on sound science and quality risk management. The application of the QbD 
principles in TE bioprocess development has been brought forward as a strategy to ensure 
that manufactured TE products will possess predefined quality characteristics addressing 
emerging regulatory requirements and ensuring a functional in vivo behavior, facilitating 
thus the road to clinical use and commercialization (Rathore and Winkle, 2009). Primary QbD 
considerations that need to be taken into account while designing bioprocesses should focus 
on: (i) the materials to be used (process components), (ii) the various manipulations and 
assessments of the materials (process requirements), and (iii) the performance of the output 
product(s) (process function), for TE products, regenerative potential upon implantation 
(Figure 2).  
 
Figure 2: Design principles for stem cell and tissue engineering bioprocessing (Placzek et al., 
(2009). J. R. Soc. Interface 6,209-232.). 
 
Understanding and refining of the manufacturing process, includes: 
• To explore and identify, the material attributes and process parameters that can 
have an effect on final TE product critical quality attributes (CQAs)  
• To determine functional relationships that link critical quality attributes to critical 
process parameters (CPP)  
 
This means that out of a range of final quality characteristics of a TE product (quality target 
profile) only a subset may be linked to its efficacy and therapeutic potential, and should be 
therefore controlled and built in to during its manufacturing.  This should be carried out for 
each process step involved in the manufacturing of TE products. For instance homogeneity, 
during the scaffold seeding process step, may be a more important quality attribute than the 
seeded cell number for the therapeutic value of the TE construct, and therefore should be 
termed a CQA. This means that the manufacturer should guarantee homogeneity prior to 
maximizing cell presence. It should be noted that the quality attributes of upstream 
processes will affect the performance of subsequent processes but also end-product quality 
profile and its performance in vivo. Those TE product quality attributes that will result in the 
desirable in vivo behavior should be identified and included in the optimization loop.    
One of the most important concepts in QbD is termed as ‘design space’ and its definition 
was given by the international conference on harmonization of technical requirements for 
registration of pharmaceuticals for human use ((ICH) Q8 guidance document), as ‘‘the 
multidimensional combination and interaction of input variables that have been 
demonstrated to provide an assurance of quality’’ (FDA, 2006, 2009). So  
Figure 3: Typical approach for QbD implementation in bioprocess development and the role 
of multifactorial design of experiments and analysis. A case study for bone tissue engineering 
is shown. (Figure adapted from Mercier et al. (2014) Trends in Biotechnology. 
http://dx.doi.org/10.1016/j.tibtech.2014.03.008).  
 
Multifactorial design of experiments (DoE) is a component of QbD strategies and has been 
suggested as an important tool to develop efficient procedures that enable multiple factor 
experiments. As TE process and products intrinsically consist of a multitude of variables, DoE 
allows data to be obtained in such a way that it yields consistent and objective conclusions 
on the involvement and statistical significance of all investigated parameters but also of their 
interactions. Hence process parameters can be linked with TE product quality attributes via 
statistical correlations named response surfaces. Furthermore, DoE requires a smaller 
number of experimental runs, while, at the same time, covering a broader knowledge space 
than a one factor at a time approach. DoE has been used for optimizing complex medium 
compositions for stem cell culture (Lim et al., 2012). Multifactorial DoE was employed to 
investigate the effect of inoculation (seeding) density and agitation rate for stirred 
suspension bioreactors while expanding hESC aggregates, Significant interaction effects 
between inoculation density and agitation rate specifically in the case of exponential growth 
rates was observed. This study showed that a stepwise optimization may result in missing 
out on the real optimal operation regime (Hunt et al., 2014).   
 
23.1.2 Allogeneic vs autologous strategies 
TE therapies are often divided into two main categories: ‘patient-specific’/autologous and 
‘off-the-shelf’/allogeneic. (Wang et al., 2013a). Pioneering cell therapies (e.g. blood cell 
transfusions, bone marrow transplantation) were ‘patient-specific’, due to the need for 
histocompatibility matching. More recent therapies, however, are based in cell types that 
are low immunogenic (e.g. MSCs) and could therefore be more amenable to the 
development of ‘off-the-shelf’ products, more similar to traditional biopharmaceutical 
products (see 23.1.2). An ‘off-the-shelf’ cell therapy product is likely to be mass produced in 
large-scale processes, taking advantage of bioprocess technology and also efficient scale-up 
strategies. The manufacturing process usually involves the establishment of master and 
working cell banks (facilities that stores cells of specific genome for the purpose of future 
use in a product or medicinal needs) that will then be used for the production of large 
numbers of cells for subsequent processing. Cells will need to go through a method of 
isolation and banking, followed by bioprocessing (expansion, controlled differentiation and 
sorting) in a centralized manufacturing facility to produce the cell and neotissue type of 
choice for clinical use (Figure. 4). In contrast, ‘patient-specific’ therapies are based in 
autologous strategies or in tight histocompatibility matching and thus production is likely to 
be performed on an individual basis (Figure 4).  
Each of these approaches will likely require different solutions in terms of bioprocessing. 
Scalability can be implemented either in volume based metrics (scale-up) or in unit based 
metric (scale-out). ‘Off-the-shelf’ therapeutic products will most likely be manufactured 
based on a ‘scale-up’ strategy, which consists in the development and optimization of cell 
processes that begin at a small scale while subsequently, progressively increase the volume 
of the system, while maintaining the efficiency of the process. This approach, however, may 
not be appropriate for ‘patient-specific’ therapies, which will have to be ‘scaled-out’ in 
tightly controlled bioprocesses. This means that the process will have to be extensively 
replicated to increase the final cell number due to the large number of strictly parallel 
culture events. Also cell performance unpredictability across this parallel processing will 
have to be taken into account due to ‘donor to donor’ variability. However in the context of 
‘allogeneic’ Tissue Engineering a combined approach composed of an initial step aiming at 
scale-up for cell expansion, followed by a ‘scaled-out’ perfusion culture for subsequent 
differentiation stages or ‘neotissue’ formation, could be followed. 
 
 Figure 4: (A) Flow chart for the production of an ‘off-the-shelf’ cell therapy product. Allogeneic treatments are likely to be mass-produced using large-scale bioprocessing. (B) Flow chart for the production of a ‘patient-specific’ cell therapy product. Such therapies are based in autologous strategies or in tight histocompatibility matching, and thus production is likely to be performed on an individual basis. (Adapted from Fernandes et al. Stem cell bioprocessing for regenerative medicine. J Chem Technol Biotechnol 2014; 89: 34–47).  
23.2 Bioreactor systems for TE product manufacturing  
Bioreactors as already discussed, will play a crucial role for TE product development. They 
provide the means to overcome limitations of conventional manual methods by (i) delivering 
sufficient cell numbers for multiple doses per batch and hence provide scale up potential 
(Yeatts and Fisher, 2011, Zweigerdt et al., 2011, Wang et al., 2013b) (ii) helping to develop 
structurally defined and functionally effective complex 3D engineered constructs at the 
patient-scale using scale-out strategies(Wendt et al., 2009, Salter et al., 2012). The ability to 
develop automated bioreactor systems with steady-state control of bioprocess parameters 
such as flow rate/shear stress, dissolved oxygen tension, pressure drop (for perfusion 
bioreactor systems) and nutrient supply minimizes complexity and variability of the 
environment that the cells will experience (Martin et al., 2009, dos Santos et al., 2013). At 
present commercial platforms that succeeded in automating 2D cell culture such as 
Fraunhofer’s – ‘The Tissue Factory’ (http://www.tissue-
factory.com/en/The_Tissue_Factory.html) are available, showing the maturation of the field. 
However, automation will ultimately rely on information provided by the use of closed 
bioreactor systems that incorporate non-invasive online monitoring modalities. These 
modalities will allow the follow up of the quality characteristics of manufactured ATMPs 
during stem cell culture. Reproducible bioprocesses that will deliver the quantity and quality 
of the required cellular and tissue product should be the cornerstone for successful 
translation strategies (Yeo et al., 2013). 
23.2.1 Bioreactors for allogeneic strategies 
Allogeneic products will most likely be produced in large quantities and will therefore 
require suspension culture systems that will allow for scale-up in order to meet the demand. 
Bioreactor platforms available for producing adherent cells — including planar technologies, 
packed-bed systems, and suspension platforms such as microcarriers and aggregate cultures 
— have been employed for their potential to satisfy batch requirements at different scales. 
Microcarrier based bioreactor systems such as stirred tanks (Chen et al., 2013b, dos Santos 
et al., 2011) and spinner flasks (stirred suspension bioreactors) (dos Santos et al., 2011) and 
also wave bags (Timmins et al., 2012) have been successfully used for human mesenchymal 
stem cell expansion (MSC). Recently a  number of studies employed xeno-free components 
for the expansion of stromal MSCs as well as for human pluripotent cells (hPS) cells (Fan et 
al., 2014) and induced pluripotent cells (iPS) cells (Wang et al., 2013b) showing alignment 
with GMP requirements. Cell expansion using 3D aggregates has been also achieved in shake 
flasks for MSC (Frith et al., 2010) and hPS cells (Abbasalizadeh et al., 2012b) and in hollow 
fiber systems (Nold et al., 2013) with the retention of their differentiation potential (Figure 
3). Furthermore commercial stem cell expansion systems already exist. These platforms, like 
the Terumo Quantum® hollow fiber and the single-use Integrity Xpansion™ multiplate 
bioreactor system (see Figure 5),  provide a GMP platform with enhanced reproducibility and 
scalability. 
Type Advantages Disadvantages Scale-up / Scale-out 
Stirred 
suspension  
Homogeneity in culture 
environment due to mixing. 




Sensor readouts may prove 
inaccurate due to diffusion 
within 3D aggregates 
Scale up 
Wave bag  Disposable minimizes Cost. Scale up 
contamination risks. 
Easy to scale up 
Control of process 
parameters. 
Fixed bed / 
perfusion 
Allows cell - cell and cell-ECM 
interactions.  
Incorporation of bioactive 
scaffolds. 
Direct control over shear 
stress development.  
Accurate sensor read outs at 
the outlet of the bioreactors. 
Low volume 
Spatial gradient build-up.  
No sampling of cells is 
possible during culture. 
Difficulties in cell harvest 
Scale out 
Hollow fibre  
Easy to monitor and control. 
Low shear stress. 
 
Gradient build up at the 
hollow fibre interface. 
3D cell growth may alter 




Allows image follow up. 
Close to the low risk 
commonly used paradigm of 
the T-flask. 
Non physiological cell 
culture environment 
Difficulties in cell harvest  
Scale up 
Table 3: Bioreactor systems for cell culture advantages disadvantages role in the TE 
manufacturing pipeline 
23.2.2 Bioreactors for autologous strategies  
As the reintroduction of cells to the patient will require a rapid in vitro stage prior to 
implantation, tightly controlled systems will providing reliable monitoring potential should 
be used. For the cells-seeded-on-3D-scaffold paradigm the flow-through perfusion 
bioreactor is the reactor of choice (Marolt et al., 2012). Upon cell attachment to the 
carrier/scaffold, packed-bed perfusion systems provide continuous control options that 
overcome the limitations of traditional, standard culture methodologies. A broad range of 
variations on these bioreactor systems has been described to date in literature for the 
production of three dimensional neotissue constructs (Frohlich et al., 2010, Grayson et al., 
2010, Papantoniou et al., 2012, Kim and Ma, 2012). For example bone repair applications via 
the intramembranous (Yeatts et al., 2014, Janssen et al., 2010) as well as endochondral bone 
forming (Scotti et al., 2013) pathway have been reported upon implantation of human 
mesenchymal stem cells expanded in perfusion bioreactors in animal models  
Figure 5: Scalable platforms for integrated expansion and differentiation of hPSCs including integrated expansion and differentiation of hPSCs in dynamic adherent culture systems (A) and suspension culture systems (B) comprising encapsulation technology, microcarrier based cultures, and aggregate culture in stirred suspension bioreactors. Differentiation could be initiated after reaching desired undifferentiated cell numbers (C) by replacing the expansion media with differentiation media for early differentiation in the same expansion culture system or dissociating the cell aggregates in aggregate culture systems and transferring the single cells to high-throughput perfusion systems or micro-patterned cell aggregates based on targeted differentiation (D) and then starting functional maturation steps using different morphogens to produce target progenitor or terminally differentiated cells (E). (From (Saeed A and Baharvand H, (2013) Biotechnology Advances, 31, 1600-23)).  
23.3 Quality control for TE products – a multiscale approach 
TE product characterization and analysis will be of higher complexity than for other 
biochemically derived biological products. Moreover quality control (QC) is of high 
importance due to potential manufacturing process variability and the living nature of the 
product. The development of therapeutic stem cell containing products such as 3D TE 
constructs, will require insightful QC that will guarantee identity, quality, purity, safety and 
potency. In most cases a QC pipeline will also help to further optimize the manufacturing 
processes. Cell identity is normally measured by marker gene and protein expression 
analysis using quantitative real time polymerase chain reaction (qPCR), enzyme-linked 
immunosorbent assay (ELISA) and flow cytometry. For cells that satisfy this standard set of 
identity criteria, multilineage differentiation assays that are typically associated with stem 
cell properties will be needed to further identify stem cell populations. For example 
mesenchymal stem cells should be able to differentiate to the osteogenic, adipogenic, and 
chondrogenic lineage. However these established analysis methods are not the only cell-
related QC options, non-invasive measurements could also provide information regarding 
the properties of the cultured cells and tissue. Upon thorough validation they could be 
sufficient for the determination of TE product quality attributes. For example such methods 
have been employed for the determination of cell content during perfusion bioreactor 
operation via metabolic activity assays (Zhou et al., 2013b) oxygen consumption (Santoro et 
al., 2012, Lambrechts et al., 2014) heat production due to cell growth (Santoro et al., 2011) 
and metabolic imaging (Ward et al., 2013). However in order to obtain more insightful and 
accurate information, where volume averaged sensor read outs might prove insufficient, 
fluorescent based imaging of oxygen sensitive fluorescent microbeads (Lambrechts et al., 
2013) could fill in the gap.  
A crucial aspect towards non-invasive QC for TE products would the development of novel 
methods or the incorporation of existing technologies (ELISA, mass spectrometry) in 
bioreactor setups that would allow online biochemical readouts (i.e., gene expression, 
protein secretion, cell surface antigen expression). It should be noted that when dealing with 
clinical delivery of TE products, quality properties regarding spatial properties should also be 
taken into account. For example extracellular matrix quantity and its distribution throughout 
the produced TE construct require a tailored characterization approach. Imaging techniques 
such as computed tomography could provide possibilities to obtain in a non-destructive way 
this information for TE constructs (Papantoniou et al., 2013). Overall the QC strategy 
followed will be determined by the manufacturing context that will be required for the 
clinical delivery of the TE product (Figure 6).  
Figure 6: Quality control strategies for allogeneic and autologous TE products. For the first strategy representative lots could be tested due to the homogeneous starting cell population. In the second case a more stringent quality control strategy should be employed since the variability introduced in cell populations due to the variety of donors will impact on process performance and TE product quality attributes (Figure from Brandenberger R, Burger S, Campbell A, Fong T, Lapinskas E, Rowley JA.2011. Cell therapy Bioprocessing. BioProcess International, Vol. 9, No. S1, 2011, 30–37) 
23.4 Online data-based monitoring- cross-talk between process parameters and TE 
construct quality attributes 
On-line non-invasive bioprocess monitoring has gained attention since the FDA launched the 
process analytical technology guidelines (PAT initiative) in which biopharmaceutical 
companies are encouraged to adopt monitoring tools to ensure pre-defined final product 
quality (Teixeira et al., 2009). However, monitoring is only the first step towards the 
controlled production of tissue constructs with a robust clinical success rate. Ultimately an 
improved control of the TE construct quality is envisioned through the measuring, modeling 
and managing of critical cell culture parameters (M3C) (Carrondo et al., 2012). The 
complexity and inherent variability of biological systems makes their control a challenging 
task. This becomes even more challenging when in vitro processes aim to mimic the 
developmental stages of embryo or organ maturation requiring spatial and temporal 
manipulation of the bioprocess (Lenas et al., 2009, Ingber et al., 2006). However interesting 
opportunities arise within GMP environments for TE production as large amounts of high-
quality data related to stem cell and TE construct properties will be continuously gathered. 
Examples are, among others, measurements on environmental culture conditions (dO2, pH, 
CO2), image analysis (i.e. confluency, morphological features, collagen presence) and -omics 
datasets. With the rise of automated cell culture processes the amount of datasets will only 
increase, both sample-wise due to higher sampling frequency but also parameter-wise due 
to the development of new modalities. Monitoring of critical culture parameters on its own 
is key for process control and fault detection, but the real challenge will be to translate 
common process read-outs into interpretable TE construct quality attributes. At a final stage 
this could provide the potential to link end TE product characteristics to in vivo performance 
and ultimately, predict in vivo outcome upon implantation. 
Figure 7: 
Schematic ranking of the trade-off between the complexity of analysis techniques and the 
level of information they can provide. The selection of the most appropriate analysis 
technique used is application specific. The challenge will be to gain the right level of 
information with (a combination of) the most accessible technologies. 
 
23.4.1 Image data read outs 
Visual inspection, either manual or automated, is common practice to assess cellular 
characteristics and can often be linked to for example stem cell differentiation. Certain 
processes developments, such as the reprogramming success rate of iPS cells (Smith et al., 
2010) or the likelihood of differentiation commitment (Roccio et al., 2013) can be non-
destructively assessed in early culture phases with imaging based algorithms. The next step 
is to leverage this information from monitoring algorithms to predict quality attributes of the 
construct. For example Matsuoka et al. (Matsuoka et al., 2013) used phase-contrast 
microcopy to obtain time-series of morphological changes to subsequently develop a 
prediction model of osteogenic differentiation. In this model computational machine 
learning (ridge regression) was applied to make morphology-based predictions of cellular 
quality (ALP-activity and mineral deposition at day 14 and 21 respectively after osteogenic 
induction) taking into account patient specific variance (Figure 8). However this method is 
only suitable for 2D cell culture systems. The extra dimension when culturing in 3D TE 
constructs would require for more powerful imaging modalities such as computed 
tomography systems to be incorporated in bioreactor operation (Hagenmuller et al., 2010) 
hence obtaining spatial information regarding the whole tissue under development.   
  
Figure 8: Historical image data collected from a range of patients were used to train 
algprithms (Scenario I). Images from all passages of patient 3 were used for prediction. B 
Ongoing prediction scheme: Trained by historical patient datasets and a partial dataset from 
the new patient. For example for the prediction of cell potential of patient 3, Scheme I uses 
images patient 1 and 2 only. Scheme II uses images of patient 1 and 2, together with some 
images of patient 3. (Matsuoka et al., PLOS One, 2013. DOI: 10.1371/journal.pone.0055082)   
 
23.4.2 Online sensor data read outs 
The incorporation of multiple sensors to frequently monitor environmental culture 
conditions during culture has been suggested by PAT strategies. Although effective for 
process monitoring and fault detection, dO2 and pH read-outs are no direct measures of cell 
or tissue construct quality. Several strategies exist to indirectly extract more quantitative 
information on TE quality attributes such as cell number and cellular activity based on 
oxygen measurements in bioreactors (Santoro et al., 2012). Volkmer et al. (Volkmer et al., 
2012) not only monitored the oxygen concentration within a TE scaffold, but also controlled 
the cellular microenvironment based on an oxygen concentration triggered feedback loop to 
steer the medium feed rate. However, provided the biological complexity of cells or a TE 
construct, it is unlikely that environmental physicochemical measurements alone will deliver 
a detailed signature of the construct quality and be able to robustly predict the clinical 
effectiveness of the construct. Meanwhile dynamics in metabolite accumulation or nutrient 
consumption have the potential to yield more in depth assessment of the cellular status 
(Patti et al., 2012). Glucose/lactate measurements (Schop et al., 2009), soluble signaling 
factors (Csaszar et al., 2013) and metabolic assays in bioreactors are currently being 
investigated (Zhou et al., 2013b). By measuring cellular metabolites that are secreted into 
the medium, so called exometabolomics, non-invasive information on the intracellular state 
up to the proteomic and genomic level can be obtained. Metabolomics and especially 
exometabolomics have great potential to become a non-invasive holistic physicochemical 
characterization of TE cultures.  
23.4.3 Online data treatment 
Ultimately the development of data-based algorithms that will be able to process data on 
line/ in real time, are essential for the automatic adjustment of bioprocess parameters based 
on variations of cell behavior (Carrondo et al., 2012). This evolution will be crucial for the 
final optimization of ATMP manufacturing protocols and for the delivery of reproducible high 
quality ATMP end products. Such an approach, in synergy with already existing mechanistic 
approaches, will enhance our understanding of the highly complex TE bioprocesses and 
allow the development of predictive models for in vitro cell behavior, and hopefully in vivo 
outcome  
In order to increase the TE construct quality, there is a need for mathematical approaches 
that are able to systematically integrate multiple data sources and provide us with predictive 
models for optimization and control of the TE processes. Generally, models can be divided in 
mechanistic models (deductive approach based on a priori knowledge) and data-driven 
models (inductive approach based on observed data). From the former, many examples can 
be found within the TE field under the form of conservation equations, stoichiometric 
models, reaction kinetics, etc. Data-based models are found within the biological process 
technology under the form of regression models, principal component analysis and neural 
networks. Mechanistic models may be superior in providing insight in the system under 
consideration however they require a significant cost of development, more difficult 
parameterization and are generally harder to solve. Data-based models provide less insight 
in the system, but in situations where the data logging surpasses the speed of analysis they 
provide an ideal basis for online prediction and control. An interesting direction regarding 
the GMP production of TE constructs, where both increased automation and process 
understanding are pursued, is the data-based mechanistic approach in which the initial 
“black-box” model identification stage is followed by a mechanistic interpretation of the 
model parameters and model structure (Table 3). This approach generally results in 
physically/biologically meaningful low order models that are able to describe the dominant 
behavior of a biological system and can be used in real-time controllers. 
 Mechanistic 
models Data-based models 
Data-based 
mechanistic 
Providing insight in 
system +++ --- + 
Cost of development --- ++ - 
Online interrogation -- ++ ++ 
Controller friendly + +++ +++ 






Table 3: Advantages and disadvantages of various modeling approaches. 
23.5 Enhancing in vivo performance: an in silico mediated approach for TE product design  
The challenge the TE field now faces is to translate (in vivo) regenerative processes to an in 
vitro environment on an engineering scale, thus making the process measurable and 
controllable with a limited number of parameters. Nature uses a very complex system of 
regulatory mechanisms compounded by a huge amount of redundancy to deal with the 
panoply of internal and external influences. The intricate interplay between all these factors 
is too complex to be interpreted without the help of computational, in silico, modeling 
(Jukes et al., 2008, Ingber et al., 2006). 
23.5.1 Model variety and classification 
In silico models exist in many shapes and forms, allowing for very different questions to be 
tackled. Typically, models are categorized based on the information they use to build the 
model (Janes et al., 2004).  When using only experimental data (such as the large data sets 
generated by high throughput techniques), models are called empirical or data-driven. When 
they are based on researcher interpretation of the data, and the proposed hypotheses on 
the mechanisms of action, we talk about mechanistic or hypothesis-driven models.  Another 
classification often used for in silico models is based on the spatio-temporal scales that are 
encompassed. Intracellular or subcellular models most often focus on the regulatory 
networks defining cellular behavior (Kinney and McDevitt, 2013). Cellular models consider 
cells as individual agents that can interact with each other and their environment. A level 
higher, the tissue/organ level, cells are represented in a more continuous way by means of 
their density.  This level is typically suited to look at the overall effect of cellular actions and 
interactions in the form of neotissue formation in TE scaffolds, the influence of external 
influences such as mechanical modulators, nutrient supply and chemicals.  Also the influence 
of the in vivo environment on the TE product is described at this level.  Finally, at the 
population level, in silico clinical trials are increasingly carried out, especially in the field of 
critical care and cancer treatments (Roelofs et al., 2012), to optimize the trial design and 
patient stratification as to limit the expenses and avoid negative side-effects as much as 
possible.   
Given the current underlying difficulty in estimating parameter values, many models may 
remain limited in the mechanistic insight they provide and in their capability to predict 
system dynamics in unforeseen conditions. To investigate the impact of the chosen 
parameter values on the simulation results, sensitivity analyses should be carried out. 
Sensitivity analyses appear under many different forms, ranging from the most frequently 
used one-at-the-time (OAT) analysis where only one parameter is altered in each simulation 
to multifactorial DoE approaches run providing information on the interaction between 
experimental process parameters. Finally, in order to explicitly account for the noisy 
character of the data and processes, stochasticity can be introduced into the in silico models. 
Explicitly taking into account the uncertainty in the experimental data, can result in the 
retrieval of a wide range of parameter sets, all capable of fitting the data. Perhaps 
surprisingly, some predictions will still be very well constrained even in the face of this 
enormous parameter uncertainty, a property which was coined ‘sloppy’ (Gutenkunst et al., 
2007). Even though sloppiness is not unique to biological systems, it is particularly relevant 
to biology because the collective behavior of most biological systems is much easier to 
measure in vivo than the values of individual parameters. Using sloppy parameter analysis 
(SPA), concrete predictions can be extracted from models long before their parameters are 
even roughly known (Brown et al., 2004), and when a system is not already well-understood, 
it can be more profitable to design experiments to directly improve predictions of interesting 
system behavior rather than to improve estimates of parameters. In order for TE to benefit 
maximally from the advantages in silico modeling can bring, an integrative approach is 
indispensable in which the development of the in vitro, in vivo and in silico components of 
research go hand in hand from the start.     
23.5.2 In silico implantation of TE constructs 
The host environment is a crucial component of the TE design strategy and the ability to 
predict the interaction between the host and the TE product is pivotal for many of the 
processes discussed in this chapter. In silico models allow to combine knowledge on basic 
biology and TE product behavior to study the effect of e.g. in vivo scaffold dissolution on 
local in vivo cell biology (Carlier et al., 2011) and/or blood vessel formation (Checa and 
Prendergast, 2010). Patients presenting with structurally and/or genetically challenged 
healing environments pose additional challenges to the TE strategy but it is most often in 
those patients that normal healing is impaired and thus TE solutions are required.  In silico 
models are applied to both study the etiology of impaired healing (Geris et al., 2010), and to 
design novel therapeutic strategies that are able to overcome the additional patient-specific 
hurdles. These models provide an additional level of (mechanistic) understanding to the 
data-driven empirical models which use multiparametric techniques to link in vitro 
characteristics to observed in vivo behavior. Taking into account that parameter 
quantification of scale-specific models is already difficult, the problem is even worse for 
multiscale models where parameters have to be defined at different scales. It is widely 
accepted that as more quantitative experimental data become available to build and 
constrain the parameter values, the models will be more likely to describe observed 
behaviors accurately.  
23.5.3 Whole bioprocess virtual TE 
One important application of mathematical models is the study of individual components of 
TE products such as the cells and the scaffold. Biological systems (TE product behavior being 
one of them) are naturally multiscale and to understand their behavior fully we must 
understand the interaction of a number of processes that may occur on diverse temporal 
and spatial scales. Models focusing on the cell compartment are used to identify the 
biological state of the cell based using statistical methods applied to large data sets (Mentink 
et al., 2013) or more mechanistic methods built on knowledge of specific relevant pathways. 
Combining both approaches allows identify the precise state of the cells of the TE product 
but also of optimized culture conditions providing the potential to push or keep cells in the 
desired state (see state of the art experiment, (Csaszar et al., 2012)). Models regarding the 
scaffold, focus on the mechanical (Song et al., 2013), biochemical (Demol et al., 2011, Bjork 
and Tranquillo, 2009) and morphological aspects (Saito et al., 2012) of its design with the 
aim of understanding its influence on the behavior of the seeded cells. More and more these 
in silico models are combined with a description of the physical environment that  
bioreactors presents to the TE product during the in vitro culture process (in terms of e.g. 
fluid flow, mechanical stimulation and mass transport)(Causin et al., 2013). Optimization of 
initial cell seeding and initial cellular differentiation is predicted through the adaptation of 
the bioreactor protocol and scaffold morphology (Spencer et al., 2013).  Additionally, 
neotissue growth during extended culture of the TE products can be captured by 
multiphysics models combining a description of the physical bioreactor environment with a 
mechanistic description of cellular behavior and matrix production (Guyot et al., 2014) 
(Figure 9). Once validated, these multi-physics models can become an inherent part of 
bioprocess development loop providing an insight view in the TE product in culture by 
allowing to liaise the bioreactor sensor read-outs (e.g. pressure drop) with the biological 
interpretation in terms of local neotissue growth in the TE product.  
Figure 9: In vitro – in silico – in vivo optimization loop.  The in vitro part (left) shows the raw materials of TE product manufacturing: cells (showing a gene regulatory network, Kerkhofs et al, PLoS ONE 2012), biomaterials (i.e. CaP-collagen carrier visualized with nano-Computed Tomography, courtesy G. Kerkchofs) and process environment (schematic representation of perfusion bioreactor set-up).  The properties of these raw materials can be optimized using in silico models for all the constituents of a TE product (middle): cells (aggregating on a microbead, Smeets et al, CMBBE 2013), biomaterials (degradation & calcium release from calcium containing scaffolds, courtesy V. Manhas) and process environment (neotissue growth in scaffold, Guyot et al, BMMB 2014). Additionally, in silico models can combine the raw materials and make predictions on optimal combinations leading to maximal bone formation in vivo (influence of seeding density on bone formation in calcium containing scaffolds, Carlier et al, Acta Biomaterialia 2011). In vivo experiments (bone formation in CaP scaffolds, Roberts et al, Biomat 2012) close the in vitro-in silico-in vivo optimization loop and confirm the in silico predictions or suggest model adaptations and in more focused vitro experiments. 
23.6 Downstream processing in TE manufacturing 
As already discussed, automation of current lab scale processes for regenerative medicine 
and tissue engineering is widely considered to be essential for the successful clinical 
implementation and industrial translation of these emerging technologies (Ratcliffe et al., 
2011, Abbasalizadeh and Baharvand, 2013). As already discussed in this chapter, the use of 
bioreactor systems is considered to be an indispensable step for cell culture and expansion 
as part of TE strategies. Although bioreactor systems already enable automated cell 
expansion in a GMP environment, a series of manual, operator dependent down-stream 
post processing steps are still required to deliver a finalized product. For example cell 
harvest steps for the recovery of cells from microcarriers or 3D cell aggregates and also 
subsequent seeding steps will be needed to reach the end product. Process steps such as cell 
harvest and up-concentration, can be managed on a lab scale for a limited amount of 
systems. However this lab scale approach poses severe limitations when scale-up and scale-
out challenges need to be addressed, as it impacts on the quality of the manufactured TE 
products. Therefore, next to continuing to develop and optimize strategies enabling GMP 
compliant cell expansion, the development of suitable down-stream processing methods 
should receive equal attention. 
23.6.1 Cell harvest/recovery 
Cell harvest is proving to be one of the most challenging and critical process steps limiting 
the industrial implementation of current processes (Cierpka et al., 2013, Liu et al., 2013). 
Despite the development and intensive research activities in bioreactor technology 
development, subsequent processes are currently lacking equal attention. Enzymatic 
retrieval of the cells from the culture surface is the gold standard up till now despite the 
associated disadvantages such as (i) potential damage to the cells, (ii) cost of the procedure 
and (iii) availability of the GMP grade proteolytic dissociation enzymes (Abbasalizadeh and 
Baharvand, 2013, Cierpka et al., 2013). The long standing use of these reagents for cell 
recovery has however resulted in the development of highly efficient, minimally invasive 
methodologies which have already been successfully been implemented in commercial 
available systems (Roberts et al., 2012, Jones et al., 2013). Similar methodologies have been 
developed for micro-carrier based cell expansion (Chen et al., 2013a, Goh et al., 2013, Zhou 
et al., 2013a) although the versatility of this culture platform also enables to develop novel, 
enzyme independent, cell recovery methods based on for example temperature dependent 
behavior of the surface (Tamura et al., 2012). Recently, the use of carrier-free culture 
methods for anchorage dependent cells based on cell aggregate formation has emerged as a 
novel, promising concept for cell culture. Although the classical enzymatic methods can be 
used to recover cells expanded in these culture systems (Abbasalizadeh et al., 2012a), the 
potential to develop enzyme-free methodologies has significant advantages such as the 
reduced consumable cost, reduced final volumes and the removal of a potential harmful 
reagent. Although enzyme-free methods for aggregate dissociation are currently being 
developed, they are often associated with a significant decrease in viability and other 
adverse effects ranging from spontaneous differentiation to apoptosis (Abbasalizadeh and 
Baharvand, 2013, Ratcliffe et al., 2011, Cierpka et al., 2013). Novel methods are however 
being developed which might enable enzyme free cell recovery from micro-carrier and 
aggregate culture systems (Wallman et al., 2011). However, for 2D based systems such as 
multiplate stacks and hollow fibre systems enzymatic cell recovery will probably remain the 
gold standard. It should be noted that enzymatic dissociation media will require further 
optimization both in composition and concentrations and a validation in a 3D context should 
be also carried out. Recently Nienow et al (2014) introduced a dynamic harvest methodology 
to retrieve expanded cells from microcarriers. However, it is evident that only minimal 
information is currently available and there is ample space for cell harvest process 
optimization research efforts (Chen et al., 2013b). 
23.6.2 Volume reduction 
Volume reduction and washing process requirements will be directly linked to the harvest 
volume, which will be a consequence of the bioreactor platform employed for cell culture 
and also the volumes used during the harvest process. Independent of the culture and 
harvest methodology used, the recovered cells will in most cases be suspended in large 
volumes of medium requiring subsequent up-concentration prior to further processing. 
Dependent on the final application of the process, different strategies might be of interest 
although mostly the physical differences between the cells and the fluid in which they are 
suspended are exploited. When the process targets cell expansion for allogeneic products a 
closed production pipeline capable of continuously processing large volumes of cells should 
be aimed at such as continuous centrifugation (used for the collection of blood plasma (Burd 
and Schembri, 1993)) or aqueous two-phase separation systems (based on solubility 
differences (Gonzalez-Gonzalez and Rito-Palomares, 2013)). Other, more recent, 
developments for constant cell separation aim at the use of microfluidic based devices such 
as shown in Figure 10 although significant progress still needs to be made in up and out 
scaling prior to industrial implementation (Autebert et al., 2012, Gossett et al., 2010). For 
autologous products the use of disposable systems is a more viable approach as it allows the 
use of simple, single use separation methods. At current different clinical grade expansion 
systems such as the Quantum bioreactor (Terumo BCT, USA) and VueLife culture bags 
(CellGenix, USA) use batch centrifugation for cell concentration (Rojewski et al., 2013, 
Spanholtz et al., 2011). The scale out potential of this methodology is however limited as it 
still requires a significant amount of manual handlings - and the integration of alternative 
strategies such as cross flow filtration might be required for the successful industrial 
implementation. 
Figure 10: Generalized separation methods employed in microfluidic devices. a Continuous kinetic methods depend on the rate of cell deflection perpendicular to primary channel flow. b Continuous equilibrium methods involve migration to property-dependent equilibrium positions. c Elution methods depend on forces antiparallel to primary flow to create differential retention. d sub category of equilibrium based separation methods based on differences in solubility in two different aqueous phases. Figure adapted from (Gossett et al., 2010. Anal Bioanal Chem, 397:3249–3267).  
 
23.6.3 Cell selection  
Cell selection will predominantly be of importance before the cell expansion but the use of 
mixed cell populations could require additional purification steps subsequent to the harvest. 
Although a variety of methods is available ranging from separation based on physical 
properties to the use of aptamers and advanced tag free methods. Significant advances in 
process development are still required to enable their online implementation (Diogo et al., 
2012). While separation based on physical properties such as centrifugation, aqueous two 
phase separation and filtration are reasonably high throughput these methods offer a low 
specificity, making them more suited for volume reduction than for high resolution cell 
selection (Abbasalizadeh and Baharvand, 2013, Diogo et al., 2012). Monoclonal antibody 
based techniques such as fluorescent activated cell sorting (FACS) and magnetic activated 
cell sorting (MACS) offer a significantly higher resolution although the labelling of cells with 
monoclonal antibodies might affect cell function and could induce unwanted responses 
(Abbasalizadeh and Baharvand, 2013). Aptamer based cell recognition is a more novel 
technique which might address these issues although obtaining a higher throughput 
becomes once more a limiting factor. The use of affinity chromatography based methods 
could enable the required high throughput and could also be integrated in both disposable 
systems for autologous therapy as well as in a production line for allogeneic products. In 
combination with additional recognition elements such as aptamers high specificity for the 
selection of a specific cell population could be obtained. The use of tag-free methodologies 
would however be more beneficial still. Parallelization of novel microfluidic based 
developments such as field flow fractionation and dielectrophoresis could enable high 
throughput separation of cell suspension, however these developments are still in their 
infancy and will require further development especially when scale up challenges will need 
to be faced (Abbasalizadeh and Baharvand, 2013, Fernandes et al., 2013, Diogo et al., 2012).  
23.6.4 Integrating units of operation 
Dependent on the culture system used, multiple challenges still need to be met to develop 
integrated, controlled and automated systems. Octane Biotech (Kingston, Canada) already 
delivered proof of concept with the development of the Cocoon system (Martin et al., 2009) 
which allows the automated processing of a tissue biopsy into a tissue engineered construct 
using a closed and controlled environment. As this system was developed to facilitate the 
entire process from biopsy to final tissue engineered construct it includes all required up- 
and downstream processing modules. Once commercialized, it could offer great potential for 
bringing lab scale tissue engineering processes to the clinic. However in order to efficiently 
operate and optimize inter-dependable sequences of units of operation a ‘whole-bioprocess‘ 
optimization strategy should be followed from early on in development. An understanding of 
how upstream processes will impact on the performance of subsequent process steps but 
also on final TE product quality attributes should be kept in mind during bioprocess design 
and development.   
23.7 Towards efficient TE product translation 
The term ‘advanced’ in the acronym ATMPs signifies the novelty and lack of prior history in 
dealing with living products. Hence the establishment of novel strategies that will have to 
emerge from a rapidly evolving research landscape is required. Major scientific 
breakthroughs, such as the introduction of iPS technology, can have major impact on the 
way ‘current’ manufacturing strategies may be structured up to that point. However the 
translation of scientific discoveries to clinic trials and subsequently to the market is a long 
procedure that will require input from various directions. Recent initiatives at both 
continental and global scale (European interdisciplinary summit on ATMPs, white paper 
REMEDIC, 2-3 May 2013, Vienna; Global assessment of stem cell engineering, 2014) have 
managed to conceptually streamline research developments in stem cell and tissue 
engineering into a more concrete direction towards translation to the clinic but also to the 
market. The joint ‘forces’ between academia industry and regulatory bodies will be key for 
the translation of TE products in a hospitable market/environment. Minimum requirements 
should be clearly defined and baselines given based on a constant discussion regarding 
international harmonization and standardization. Also some ‘pioneer’ products could set 
some initial guidelines towards this direction although enhanced communication and 
knowledge dissemination will be needed (See 23.1.2). Hospital exemption, minimizing 
national and subnational differences, reimbursement policies, predictive preclinical efficacy 
and safety testing, need for innovative systems for preclinical testing, product 
characterisation and product potency will have to be addressed. A recently published two 
year global survey on stem cell engineering funded by the national science foundation (US), 
concluded that there needs to be an increased role for interdisciplinary research platforms 
where biologist and engineers and the engineering approach that will provide a foundation 
for the generation of new markets and future economic growth (Nerem et al, 2014. 
doi:10.1089/ten.tea.2013.0468). The recent establishment of institutes such as the Cell 
Therapy Catapult, London, UK (https://ct.catapult.org.uk/) and the Centre of 
commercialization of regenerative medicine Toronto Canada (http://www.ccrm.ca/), shows 
a trend of integration that is required for the realization of the hopes and promises of 
regenerative medicine.  
There is need for technologies that will allow  extract information from the performance and 
fate of implanted TE constructs in order to provide minimal quality requirements that should 
be met by the TE product quality profile. This will directly provide information for process 
engineers to target and customize accordingly the production pipeline to meet minimal 
criteria as obtained from in vivo monitoring.  Regarding in vitro TE manufacturing platforms 
and practices, it may be stated that currently the production of sufficient quantities of stem 
cells (embryonic, iPS and mesenchymal) is feasible even in xenogeneic free platforms, as 
recently demonstrated by a number of publications. However further improvements in 
expansion and differentiation efficiencies based on the manipulation of process parameters 
are still achievable. Furthermore the incorporation of developmental biology principles 
during in vitro 3D TE production will require more elaborate strategies for efficient 
spatiotemporal delivery of the appropriate stimuli.  
Future challenges in bioprocessing and manufacturing will include advanced and 
sophisticated monitoring platforms that allow monitoring at the cellular level. 
Developments in monitoring and control strategies that will be tailored for specific stem cell 
types but also for more complex 3D TE construct culture, should be pursued by the 
incorporation of multiple sensors in bioreactor systems. This would provide information- rich 
processes for the manufacturing of TE products that could meet regulatory demands. 
Furthermore monitoring robust bioprocesses (hence minimized variability) can provide high 
quality, low noise data for modelers in order to make more rapid progress in the years to 
come. Modeling approaches that will be able to capture the dynamic and transient nature of 
stem cell behavior by predicting characteristics not only of the final cell populations but also 
of the 3D neotissue will be required. High throughput platforms will still be needed to 
determine optimal combinations between stem cell populations and biomaterial 
composition and texture but also for optimizing multicomponent differentiation media 
formulations.  
Recently the development of decision tools that may screen and identify optimal 
manufacturing strategies, incorporating cost of goods (CoG) was demonstrated recently for 
an allogeneic therapy production scenario were various cell expansion strategies were 
compared computationally in terms of cost efficiency (Simaria et al., 2014) Figure 11). Similar 
studies should be include more units of operation taking into account risk assessment as 
introduced by donor to donor variability and its implications, especially for autologous 
production scenaria. The integration of bioprocess economics with bioprocess optimization 
to assess the economic competitiveness of available systems (i.e. planar, microcarrier-based 
cell expansion technologies) will be an asset to map optimum TE product translation 
strategies.  
 
Figure 11: Conceptual illustration of a technology S-curve showing the evolution of expansion technologies used in cell therapy manufacture. The limits of each S-curve correspond to the amount of cells achieved by the smallest and largest size of each technology type when using the maximum number of units. Automated multi-layers refer to L-40 and cL-120. The x-axis represents qualitatively the R&D effort required for a company currently using T-flasks to change to other cell expansion technologies. (From Simaria et al., Allogeneic Cell Therapy Bioprocess Economics and Optimization: Single-Use Cell Expansion Technologies, Biotechnol. Bioeng., 111 (2014) 69-83). 
                     State of the art experiment 
Current expansion strategies, expose hematopoietic stem and progenitor cell (HSC) 
populations to uncontrolled culture environments with limited dynamics due to the 
unregulated accumulation of inhibitory endogenous factors. This results in compromises 
expansion levels that could ideally be obtained. In vitro (and in vivo) hematopoiesis is a 
dynamic and regulated process, through nonlinear feedback control. It should be noted that 
the rate of factor secretion varies widely among individual factors and does not always 
correlate with the exponential growth rates of total cell expansion. Overall a highly complex 
culture environment is developed with factor concentration dynamics following the 
dynamics of specific lineage subpopulations or resulting from multiple interacting feedback 
networks.  
In a very interesting work, Csaszar et al. (2012) used a simplified model of HSC 
differentiation in which cell fates were regulated by feedback from secreted molecule cell 
interaction networks among various cells from different points in the developmental 
hierarchy. The model was employed to develop a culture strategy by which the controlled 
and specific inhibition of negative regulators of HSC differentiation allowed the global 
control of the cell population dynamics. As a preliminary step, they identified numerous 
factors present in cultures with the ability to inhibit the expansion of HSC and HSC 
progenitor cells. In order to predict culture strategies that would maximize the abundance of 
HSC and progenitors, these factors were used as feedback candidates in the computational 
model. Using two commonly utilized bioreactor setups, namely fed-batch and perfusion 
systems, their calculations predicted that the fed-batch dilution approach would outperform 
other methods. When tested experimentally, the predicted protocol gave significantly higher 
average expansion of HSC and CD34+ progenitor cells after 12 days (Figure). 
The ability to modulate secreted factor concentrations and measure corresponding 
functional outputs of cell expansions will allow for a more precise study of links between 
specific endogenous protein secretion and lineage subpopulations and their associated cell-
cell interactions. This strategy serves as a robust clinically relevant system for rapid and 
automated in vitro cell expansion as well as a platform for further study of the regulation of 




   Figure: Computational simulations predict a Fed-batch strategy, at moderate dilution rates, to greatly reduce secreted factor concentrations enhancing cell expansion. (A–E) Simulated volume, secreted factor concentrations, and relative expansions under different media 
manipulation strategies: (F) “control” culture with complete media exchange (ME) every 4 days; (G) culture with complete media exchange every 24 hr; (H) culture with 50% media exchange every 12 hr; (F) perfusion culture with one unit of media perfused every 24 hr; (G) fed-batch culture with one unit of media added every 24 hr. Conditions (F–H) are normalized to same media and cytokine requirements (one additional unit of media every 24 hr). (F) Media volume requirements for a fed-batch culture at different constant dilution rates, assuming a 1 ml initial volume. (G) Predicted effect of increasing constant dilution rate of fed-batch strategy on secreted factor concentrations. (H) Predicted effect of increasing constant dilution rate of fed-batch strategy on population expansions.  The Fed-batch strategy was experimentally validated in vitro to give significantly improved expansion of progenitor cells (I) Schematic of experimental set-up comparing control (D = 0) strategy with 100% media exchange (ME) every 4 days to fed-batch (D = 1) strategy. (J) Expansions of TNC, CFC, and LTC-IC, after 12 days of culture. n > 5. Total nucleated cells (TNCs), colony-forming cells (CFCs), long-term culture-initiating cells (LTC-ICs).   References 
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Dear authors, Thank you very much for submitting the chapter on quality control, it is a very useful  chapter in the textbook, marking the maturation of our field to one where the products get more and more attention. There are a few points of attention: The text is rather abstract and generalistic. I think it is didactically beneficial you can weave in some practical examples. Please let a native speaker proof read the manuscript. Besides a number of grammatical errors, there are many very long sentences which makes reading it sometimes a bit difficult. There are quite a few typo’s. The legends to the figures are quite long and detailed. As part of a textbook, the images should clarify the concepts and details can be omitted when not really necessary. Please rewrite the objectives in an active form and really as objectives, e.g. instead of •       An understanding of the challenges that tissue engineered products will face at the translational phase Write •       To understand the challenges that tissue engineered products will face at the translational phase Please limit the current textbox to one figure A classical experiment textbox is missing A snapshot summary is missing  It would be great if you can upload a revised chapter within two weeks.  Best wishes, Jan de Boer  
 
 
 
 
 
 
